PRETORIA, South Africa, Aug. 1, 2017 /PRNewswire/ -- Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent ...
The Stimpod NMS460 includes a nerve-mapping pen-like probe which allows practitioners to locate nerves and evaluate the treatment progress. Xavant Technology announced that their non-invasive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results